Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis.
Jiang X, McGinley M, Johnston J, Alberts J, Bermel R, Ontaneda D, Naismith RT, Hyde R, Levitt N, van Beek J, Sun Z, Campbell N, Barro C. Jiang X, et al. Among authors: barro c. Mult Scler. 2025 Jan;31(1):81-92. doi: 10.1177/13524585241301854. Epub 2024 Dec 1. Mult Scler. 2025. PMID: 39618060
Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G, Healy BC, Saxena S, Saleh F, Paul A, Barro C, Lokhande HA, Polgar-Turcsanyi M, Anderson M, Glanz BI, Guttmann CRG, Bakshi R, Weiner HL, Chitnis T. Bose G, et al. Among authors: barro c. Mult Scler Relat Disord. 2023 Jun;74:104695. doi: 10.1016/j.msard.2023.104695. Epub 2023 Apr 2. Mult Scler Relat Disord. 2023. PMID: 37060852
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, Müller S, Pot C, Salmen A, Disanto G, Zecca C, D'Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli Ö, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maleska Maceski A, Benkert P, Kuhle J. Meier S, et al. Among authors: barro c. JAMA Neurol. 2023 Mar 1;80(3):287-297. doi: 10.1001/jamaneurol.2022.5250. JAMA Neurol. 2023. PMID: 36745446 Free PMC article.
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, Guttmann CRG, Bakshi R, Kropshofer H, Weiner HL, Chitnis T. Barro C, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):e200052. doi: 10.1212/NXI.0000000000200052. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36376097 Free PMC article.
128 results